Suchartlikitwong Sakolwan, Laoveeravat Passisd, Teerakanok Jirapat, Mingbunjerdsuk Thammasak, Thavaraputta Subhanudh, Vutthikraivit Wasawat, Thongprayoon Charat, Nugent Kenneth, Cheungpasitporn Wisit
Department of Internal Medicine, Texas Tech University Health Sciences CenterLubbockTexas.
Department of Internal Medicine, Bassett Medical CenterCooperstownNew York.
Proc (Bayl Univ Med Cent). 2018 Sep 19;31(4):447-452. doi: 10.1080/08998280.2018.1472994. eCollection 2018 Oct.
A literature search was performed through May 2017. Studies that compared the risk of developing infection (CDI) and/or the clinical outcomes of CDI in patients who received statin treatment versus those who did not receive statins were included. Ten observational studies with 37,109 patients were included. Compared to no treatment, statins reduced the risk of CDI development (odds ratio [OR] = 0.66, 95% confidence interval [CI], 0.44-0.99). However, among patients who developed CDI, the use of statins did not significantly reduce recurrent CDI risk (OR = 0.69, 95% CI, 0.28-1.71) or 30-day mortality (OR = 0.77, 95% CI, 0.51-1.14). In conclusion, our study demonstrates a significant association between statin use and a reduced risk of CDI development. However, the findings of our study suggest no significant associations between statin use and improvement in clinical outcomes of CDI. These findings might impact the clinical management and primary prevention of CDI.
截至2017年5月进行了文献检索。纳入了比较接受他汀类药物治疗的患者与未接受他汀类药物治疗的患者发生感染（艰难梭菌感染[CDI]）的风险和/或CDI临床结局的研究。纳入了10项观察性研究，共37109例患者。与未治疗相比，他汀类药物降低了CDI发生风险（比值比[OR]=0.66，95%置信区间[CI]，0.44-0.99）。然而，在发生CDI的患者中，使用他汀类药物并未显著降低CDI复发风险（OR=0.69，95% CI，0.28-1.71）或30天死亡率（OR=0.77，95% CI，0.51-1.14）。总之，我们的研究表明他汀类药物的使用与CDI发生风险降低之间存在显著关联。然而，我们的研究结果表明他汀类药物的使用与CDI临床结局改善之间无显著关联。这些发现可能会影响CDI的临床管理和一级预防。
